ArticleLipids in health and disease2025
Increased plasma ceramide levels are associated with arterial stiffness and vascular ageing: a cross-sectional study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sphingolipids and Atherosclerosis.Current atherosclerosis reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCardiovascular (CV) events pose a substantial threat to human health. Plasma ceramides have been shown to exhibit predictive value for CV events; however, its correlation with arterial stiffness had yet to be fully elucidated. This study aimed to explore the associations of plasma ceramide levels and their ratios with arterial stiffness.
methodsThis retrospective study involved participants whose ceramide levels were measured and whose arterial stiffness was assessed. Multivariate regression was used to assess the association between plasma ceramides and arterial stiffness. Restricted cubic spline (RCS) analysis was used to assess the correlation between plasma ceramide levels and arterial stiffness. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic value of plasma ceramides for arterial stiffness. Subgroup analyses were also performed.
resultsThis study included 503 patients with a mean age of 43.7 ± 10.8 years. The results showed that plasma ceramides 24:0 and 22:0 were significantly associated with arterial stiffness, as supported by multivariate regression analysis. RCS analysis revealed a potential linear relationship between plasma 24:0 ceramide and arterial stiffness (P for nonlinearity > 0.05). In contrast, a significant nonlinear correlation was found for plasma 22:0 ceramide (P for nonlinearity = 0.04). ROC analysis revealed optimal cut-off values of 1.035 µmol/L for plasma 22:0 ceramide (68.0% specificity, 67.3% sensitivity) and 3.335 µmol/L for plasma 24:0 ceramide (64.1% specificity, 74.8% sensitivity), with area under the curve (AUC) values of 0.702 and 0.724, respectively, demonstrating acceptable diagnostic performance. Additionally, subgroup analyses revealed a marked connection between serum ceramide levels and arterial stiffness, especially in male participants and individuals with normal lipid profiles.
conclusionsPlasma ceramide levels are significantly correlated with arterial stiffness, which suggests that they play a role as biomarkers for vascular ageing assessments and highlights their potential value for early prevention strategies against CV events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.